Subject Index

A23187, 133, 135, 136, 140, 243, 244, 248, 252, 254, 256, 258, 289, 312, 313, 322–326, 335–338, 379, 442–444
AA. *See* Arachidonic acid
Acetohydroxamic acids, 310–317
Acetylenic fatty acids, 388–390
N-Acetyl-LTE_4, 363, 417–419
  polar metabolites formed by, 43–67, 72
  as species-characteristic index metabolite, 73
Acetylcholine (ACh), 91–93, 98–101
Acivicin (AT-125), 96–97, 100
Adenosine, LTD_4 interaction with, 75, 77–82, 86-87
Adenylate cyclase, inhibition of LTD_4 cardiac effect by, 75–90
Adult respiratory distress syndrome (ARDS), 218, 271–274, 279–280, 340, 426
Airway hyperresponsiveness (hyperrreactivity), 282–288, 298, 304, 373, 402–404, 405–407
Airways. *See* Asthma; Bronchoconstriction; Bronchospasm; Bronchus; *and under* Lung *and* Pulmonary
Allergic rhinitis, 339–340
Allergy
  leukotrienes and, 1
  new mechanism of HC actions in, 456–457
Anaphylactic shock
  endogenous leukotriene production during, 43, 59–62, 65
  platelet-activating factor and, 133, 136–140
Anaphylaxis. *See* Slow-reacting substance of anaphylaxis
Antagonists, leukotriene, 306, 374–376
  antigen-induced bronchial and tracheal contractions and, 408–410
  versus bronchial asthma, 363–364, 374–376
  late responses and, 262–265, 267
  new LTD_4 analogues, 438–441
  receptor-level LTB_4 analogues, 196–200
  See also FPL 55712; ICI 198,615; LY 171,883; Receptors—antagonists to
Anti-IgG, 135–137, 139
Arachidonic acid (AA)
  anti-inflammatory drugs and, 442–444
  endogenous pool of, PLA_2 from, 27–34
  5-HPETE formation from, 1, 3–6
  in γ-interferon induction, second messenger signal, 208–217
  15-LO and, 241, 243, 245, 246, 248
  LTA_4 synthesis from, 391–392
  LTC_4 conversion of, 124
  in neutrophil injury to myocardium, 104, 115–117
  PKC and calcium in release of, 379–381
  in placenta, 434-435
  in T cell activation, 201–207
  thymocytes and metabolites of, 227–239
  See also 5-Lipoxygenase—arachidonate
Aspirin, 244
Asthma. *See* Bronchial asthma
AT-125, 96–97, 100
ATP (adenosine triphosphate), 1–2, 6–7, 10

Basophils, 336, 337
BAY K 8644, 75, 77, 82, 83, 85, 87
Benoxaprofen, 309, 399
Bile
  leukotriene elimination, in, 45–47, 56–57, 59–61, 62, 65
  measurement of cysteinyl leukotrienes in, 68, 70–72
  in acute pancreatitis, 72–74
Biosynthesis of leukotrienes, 1–11
  in vascular and heart tissues, 321–324
Blood pressure, in *N*-acetyl LTE_4 study, 417–419
Blunt ocular trauma, 428–430
BN52021, 133, 137, 139
Bronchial asthma, 142, 162, 267, 273
  EPA treatment of, 353
  influx of inflammatory cells in, 337
  leukotrienes and, 282–288, 339, 356, 369, 373
  human inhalation, 373
  LO inhibitors in treatment of, 308, 313, 398–401, 408–410
  LTD_4 and, 298–306
  receptor antagonists versus, 363–364, 374–376
  See also Airways hyperresponsiveness
Bronchoalveolar lavage (BAL), 263, 266, 267, 275, 278, 279, 402–404
Bronchoconstriction, 142, 298
  allergic, 5-LO and, 260–270
  EP 10045 and, 454–455
  immunization-induced, 405–407
  leukotriene antagonists versus, 374–376
  5-LO inhibitors and, 313–314, 398–401
  See also Bronchial asthma
Bronchospasm
  "leukotriene-dependent", 313–314
  LTC_4 and, 122
  "SRS-A"-mediated, 362

Bronchus, human
effect of LT antagonists on, 408–410
leukotriene receptor antagonists and, 181–186
di-*t*-Butylphenol derivatives, 398
BW-755C, 98, 110–112, 222, 310, 312, 315, 316, 399, 401, 405–407
BW A137C, 310–315
BW A4C, 310–315
BW A797C, 310–315

Caffeic acid, 231, 233–235
Caffeine, in LTD_4 cardiac study, 83, 87
Calcium
leukotriene induction of mobilization of, 153, 156–160, 254–255
5-LO's need for, 252
LTD_4 in mobilization of, 462–464
See also A23187; Cytosolic calcium
16-Carboxy-dihydro-tetranor-*N*-acetyl LTE_4, 36–38
ω-Carboxy-LTE_4, 51, 54–56, 69–70
Carboxypeptidase A, 391–392
Cardiac dysfunction, neutrophils and, 103–121
Cardiac myocytes
neutrophil interaction with, 108–109
ventricular, cytosolic free calcium and, 75–76, 83–88
Cardiac work, LTD_4 suppression of, 75–90
Cardiovascular effects of peptide leukotrienes, 321–333
Catabolism of LTC_4, 68–70
Cavian pulmonary artery and aorta, vasomotor effects of LTC_4 and LTE_4 on, 91–102
Cell growth, LTC_4 and, 414–416
CGP 34 064A, 438–441
CGP 36 638, 438–441
Cholesterol metabolism, 411–413
Coronary arteries, peptide leukotrienes and, 329
Coronary blood flow, 138
LTD_4 suppression of, 75–90
Coronary effects of peptide leukotrienes, 321–333
Coronary spasm, 324–326, 329
Cyclooxygenase, 98, 100, 112, 115, 133, 201, 242–244, 303, 310, 315, 325, 338, 339, 431, 442
abnormal, enzyme immunoassay of, 24–25
late responses and, 261–264
Cysteinyl leukotrienes, *See* LTC_4; LTD_4; LTE_4
Cystic fibrosis, 339
Cytochrome P-450-dependent enzymes, 117
monooxygenase, 99–101
Cytokines, 224–225
Cytosolic calcium, 75–76, 83–88, 188, 190–192
Cytotoxic macrophages, 224

Degranulation, 242
Desensitization
homologous, LTD_4-induced, 462–464
of LTD_4 receptors, 158–159
2,4-Dienoyl-CoA reductase, 39–40
1,2-Dioctanoyl glycerol (DOG), 252, 253, 256

Eicosanoids
cholesterol metabolism and, 411–413
HPLC process for, 442–444
15-LO and production of, 240–241
PKC and calcium in formation of, 379–381
in thymocyte tolerance study, 227, 228, 230, 235–237
Eicosapentaenoic acid (EPA), 353, 394, 395
Eicosatetraenoic acids, 27
Endothelial cells
eicosanoids derived from, 411–413
LTC_4 binding of, 414–416
Endothelium-derived relaxing factor (EDRF), 91, 98, 100
Endotoxemia, 423–425, 426–427
Enterohepatic circulation of cysteinyl leukotrienes, 68
Enzyme immunoassays, 21–25
Enzyme regulation, 5-LO and, 1–11
Enzymes, cryptic, 240, 243–248
Eosinophils, 267, 289, 336–338
15-LO and, 241, 242
EP 10045, 454–455
Ethanol-induced damage, 315–317
ETYA (5,8,11,14-eicosatetraynoic acid), 389

Fish oil in synthesis of LTB_4, 395–397
Flash NADH fluorescence photography, 75, 76, 79–83, 86, 87
FMLP (f-met-leu-phe), 242, 289, 337
Forskolin, 77–81, 86
FPL 54257, 357
FPL 55712, 77, 83, 87, 110, 123–125, 138, 162, 174, 175, 231, 233, 235, 263–265, 267, 313, 322, 357–359, 374, 399, 408–410, 458–460
human airways and, 181–185
Fura2, 76, 77, 85

Gastric function, leukotriene inhibition and, 435–437
Gastric mucosa, 5-LO inhibitors and, 315–317
γ-Glutamyl transpeptidase (γ-GTP), 96–97, 100, 181, 335
Gout, 309

G-proteins, *See* Guanine nucleotide binding proteins
Growth factors, endothelial cells and, 411–413
Guanine nucleotide binding proteins (G-proteins), 153–155, 158, 190–193
Guanylate cyclase, 98, 100, 101, 215, 216, 224, 242, 243

Helper cell activation, 223–224
Hepatocytes, oxidative metabolism of LTE_4 by, 35–42
Hepatorenal syndrome, 72–74
Histamine, 261, 286, 291–293, 370–373, 405–407
  coronary effects of, 322–326, 329
  pulmonary artery relaxation by, 91, 92, 98–101
HPLC (high-performance liquid chromatography), 245, 246, 248, 322–324, 334, 386, 393, 402, 442–444
Human pathophysiology, role of leukotrienes in, 334–344
Hydrocortisone actions in allergy and inflammation, 456–457
Hydroperoxides, 385–387
5-Hydroperoxyeicosatetraenoic acid (5-HPETE), 142, 203, 218, 312, 321, 393
  5-LO in formation of, 1, 3–6, 9, 10
12-Hydroperoxyeicosatetraenoic acid (12-HPETE), 106, 113
15-Hydroperoxyeicosatetraenoic acid (15-HPETE), 240–242, 247
15-Hydroxyeicosatetraenoic acid (15-HETE), 240–248
ω-Hydroxy-LTE_4, 50, 54–56, 69–70
Hypersensitivity
  leukotrienes and, 352
  new 5-LO inhibitor versus, 398–401
Hypoxia, high-flow, 75, 80–82, 87

Ibuprofen, 222, 244, 245
ICI 198,615, 97, 100, 182–185, 360, 261
  LTD_4 binding of, 162–180
  structure-activity relationships based on, 458–461
IFNγ. *See* γ-Interferon
IL-1 (interleukin-1), 201, 208, 209, 215, 221–224, 233, 235
IL-2 (interleukin-2), 201, 204–205, 208, 209, 215, 222–224, 227, 231–237
Ileum, leukotriene action on, 448–451
Iloprost (prostacyclin analogue), 75, 77, 80–82, 86–87
Immune regulation
  by γ-interferon, 208
  by LTB_4, 218–226
Immune system, 15-LO's role in, 240–251
Immunological stimuli, leukotriene release by, 133–141
Immunomodulatory role of leukotrienes, 227
Index metabolites, species-characteristic, 73
Indomethacin, 97, 98, 136–138, 201, 203, 222, 244, 246, 302–303, 313, 322, 415
  late responses and, 261, 262
Inflammation
  activated neutrophils and, 103
  acute, 5-LO inhibitors and, 314–315
  late responses and, 266–267
  leukotrienes and, 1, 101, 122, 218, 334–344, 352
  LO products in, 308–309
  LTB_4 analogues and, 196, 200
  LTB_4 mediation of, PMNL and, 187–195
  new mechanism of HC actions in, 456–457
  ocular, LTB_4 and, 428–430
  PLA_2 role in, 33–34
Inflammatory bowel disease, 218
Inflammatory cells
  in acute lung injury, 271–281
  leukotriene formation in, 252–259, 335–338
Inflammatory synovial exudates, 218
Inhalation challenge, 370–373
  antigen, 374, 398, 401
Inotropic effects, 79, 86
γ-Interferon, 205, 223–224
  AA second messenger signal in, 208–217
  15-LO and, 241, 242
Interleukins. *See* IL-1; IL-2
Ionomycin, 224
Ischemia
  leukotrienes in, 101, 329
  neutrophils and, 103–121
Isoproterenol, 77, 79–81, 83–88

L648,051, 374–375
L649,923, 374
Late responses, allergen-induced, 260–270, 282, 283
Leukemia cells, homologous desensitization in, 462–464
Leukocyte and vascular-cell synthesis of leukotrienes, 122–132
Leukocytes
  leukotriene synthesis by, 122–132
  15-LO and, 244, 246
  phagocytic, 310, 311
  receptor-specific mechanisms for responses of, 345–355
Leukotrienes
  antagonists to. *See* Antagonists, leukotriene
  definitions of, 1, 218
  receptors of. *See* Receptors

types of. *See* LTA_4; LTB_4; LTC_4; LTD_4; LTE_4
Lipid peroxidation, 387
Lipoxin
biosynthesis of, 15–17, 20
definition of, 15
PLA_2 release of, 27–34
Lipoxin A (LXA), 240, 242, 243, 394
Lipoxin B (LXB), 394
Lipoxygenase
catalysis of, 385–387
enzyme immunoassays of, 21–24
IFNγ production and, 215–216
immunohistochemical studies on, 21
inhibitors of, 309–310, 313–317, 388–390
catechols, 382–384
EP 10045, 454–455
15-LO and, 242, 243
mammalian, biochemistry of, 12–26
mechanism for regulation of, 382–384
in neutrophil-mediated cardiac injury, 106–114, 117
pulmonary responses to products of, 142, 150
T cell activation and, 201–207
thymocyte tolerance and metabolites of, 227–239
5-Lipoxygenase, 133, 139, 140, 196, 204, 393
allergen-induced late responses and, 260–270
arachidonate
lymphoid cells and, 346–347
selective inhibitors of, 307–320, 398–401
calcium required by, 252
human leukocyte, ATP and, 1–11
inhibition of
by manoalide analogues, 445–447
in new anti-hypersensitivity compounds, 398–401
in vitro and *ex vivo*, 311–312
purification and properties of, 17–20
12-Lipoxygenase, purification and properties of, 13–17
15-Lipoxygenase
cryptic, 240, 243–248
immune-system role of, 240–251
Lithium, 219, 222, 223
leukotriene synthesis and, 253–255, 257–258
Liver cirrhosis, 72, 73
LTA_4 (leukotriene A_4), 1, 107–108, 126–130, 142, 218, 321, 393
LTB_4 (leukotriene B_4), 142, 242, 321, 322, 335, 414–415
in asthma, 285, 286
blunt ocular trauma from, 428–430
fish oil and tocopherol induced changes in synthesis of, 395–397
immune regulation by, 218–226
inflammatory cells and, 336–338
inhibition of synthesis of, 312
in inflammatory diseases, 308–309
metabolism of, 35
in neutrophil-mediated cardiac injury, 106–108, 112, 113
neutrophil binding of, antagonists to, 196–200
in placenta, 434–435
PMNs and, 252, 258, 345
in porcine endotoxemia, 426–427
receptor antagonists to, 356–368
receptor regulation for, 187–195
receptor-specific mechanisms for leukocyte responses to, 345–355
signal transduction process for, 154–156, 158–160
T cell production of, 201–207
in various diseases, 339–340
LTC_4 (leukotriene C_4), 253, 334–335, 338, 345, 404
in asthma, 283–286, 308
cardiovascular and metabolic effects of, 321–333
catabolism of, *in vivo*, 68–70
cell growth and, 414–416
contractile responses to, asthma and, 289–297
gastric function and, 435–437
in guinea-pig ileum, 448–451
hepatic metabolism of, 36–37
human inhalation of, 370–373
human lung tissue and, 369–370
immunological stimuli in release of, 133–141
in ischemia-induced myocardial injury, 109–113
LTF_4 and, 391–392
metabolites formed from, 43, 59, 63–66
postradiation survival and, 431–433
pulmonary vascular effects of, 142
receptor antagonists to, 356–368
inflammatory cells and, 336
vasomotor effects of, 91–102
zymosan in synthesis of, 253–258
LTD_4 (leukotriene D_4), 335, 338, 345, 415
in ARDS, 279
in asthma, 283–286, 308
bronchoconstriction induced by, 405–407
cardiovascular and metabolic effects of, 321–333
contractile responses to, asthma and, 289–297
coronary flow rate and cardiac work suppressed by, 75–90
endogenous formation of, during anaphylaxis, 43–67

gastric function and, 435–437
in guinea-pig ileum, 448–451
homologous desensitization from, 462–464
human inhalation of, 370–373
human lung tissue and, 369–370
ICI 198,615 binding of, 162–180
immunological stimuli in release of, 133–141
inhaled, human airways and, 298–306
in ischemia-induced myocardial injury, 109–113
late responses produced by, 264–265
new LT antagonists from, 438–441
pulmonary vascular effects of, 142–152
receptor antagonists to, 356–368
receptors and signal transduction of, 153–161
as species-characteristic index metabolite, 73
vascular and lymphatic pressures and, 420–422
vasomotor effects of, 91–102
LTE_4 (leukotriene E_4), 283, 286, 308, 334, 335, 338, 373
cardiovascular and metabolic effects of, 321–333
contractile responses to, asthma and, 289–297
in man, 72–74
oxidative metabolism of, 35–42
polar metabolites formed from, 43–67
receptor antagonists to, 356–368
See also N-Acetyl LTE_4
LTF_4 (leukotriene f_4), new pathway for biosynthesis of, 391–392
Lung
acute injury to, structure-function study of, 271–281
airway epithelium and diseases of, 338
15-LO in, 241, 243
membranes of, ICI 198,615 and LTD_4 binding in, 162–180
See also under Pulmonary
LVP signal, 135
LY 163,443, 358, 359
LY 171,883, 162, 174, 175, 182–185, 264, 286, 356–368, 452–453
LY 281,761, 452–453
Lymphatic pressure, LTD_4 and, 420–422
Lymphocytes, 15-LO and, 241–243
Lymphoid cells, 346–347
Lymphokines, LTB_4 induction of, 218–220

Macrophages, 208, 209, 215, 241, 242, 252, 336, 338
cytotoxic, 224
thymus, 229, 233, 235–237
Manoalide analogues, 5-LO and, 445–447
Mast cells
airways hyperresponsiveness and, 402–404
coronary vasospasm and, 324
leukotriene release by, 336, 337
15-LO and, 243
Mellitin, 243, 244
Mesenteric circulation, in *N*-aceytl LTE_4 study, 417–419
Metabolism, leukotriene, 335, 338
of LTE_4, 35–42
peptide leukotrienes, 321–333
See also ω-Oxidation
Metacholine, 285, 286, 293, 299, 301, 302
Methylene blue, 97, 98, 100
Monoclonal antibodies, anti-12-LO, 17, 21–23
Monocytes, 336, 338, 379–381
Myocardial infarction, 103–121, 122, 329
Myocardial ischemia. *See* Ischemia
Myocardial NADH fluorescence, 79–83, 86, 87

Nafazatrom, 311, 312
Natural killer (NK) cells, 224, 227, 242, 345–346
NDGA (nordihydroguaiaretic acid), 309, 311, 382–384, 436–437
Nebulization, 372
Neutrophils
in acute lung injury, 274–278
degranulation of, 242
late responses and, 267
leukotriene release by, 336, 337
LTB_4 binding to, antagonists to, 196–200
myocardial injury and, 103–121
receptor regulation for LTB_4 on, 187–195
Nifedipine, 77, 85
Nitric oxide, 91, 98
Norepinephrine, 326, 328, 420–422

Ocular inflammation, LTB_4 and, 428–430
ONO RS 411, 360, 361
β-Oxidation, 35, 38–41, 69
ω-Oxidation, 53–59, 62–66
Oxygen-derived free radicals, 104

PAF. *See* Platelet-activating factor
Pain, inflammatory, leukotrienes and, 308–309
Pancreatitis, 72–74
Penicillamine, LTD_4 dipeptidase inhibition by, 69, 71, 72
Peptidoleukotrienes. *See* LTC_4; LTD_4; LTE_4
Peritoneal cells, anti-inflammatory drugs and, 442–444
PGE and PGE_2, 201, 205, 222, 233, 252–258, 308, 338, 346

$PGF_{2\alpha}$, 373
PGI_2 (prostacyclin), 98
Phenidone, 399, 401
Phorbol esters, 188, 192
Phorbol myristate acetate (PMA), 219, 222, 243, 244, 252, 256
  in acute lung injury, 275–278
Phospholipase
  15-LO and, 243, 244, 248
  stimulation of, in monocytes, 379–381
Phospholipase A_2 (PLA_2), 201, 213–216, 242, 321, 438–441
  lipoxins and leukotrienes from, 27–34
  manoalide-analogue inhibition of, 445–447
Phospholipase C (PLC), 203, 209, 213–216, 252–253, 321
Placenta, LTB_4 and other factors in, 434–435
Platelet-activating factor (PAF), 71, 201, 242
  antagonist to, 264, 265
  cardiac anaphylaxis and, 133, 136–140
  late responses and, 265–266
  neutrophil-derived mediators and, 104–105
Platelets
  15-LO and, 241, 242, 244
  neutrophil interactions with, 106-107
  oxygenases in, 24
Polymorphonuclear leukocytes (PMN or PMNL)
  in acute lung injury, 275
  HETEs and, 246–248
  leukotriene synthesis by, 122–132, 252
  receptor systems and, 187–195, 347–352
Prostacyclin (PGI_2), 98, 115–116
Prostacyclin analogue. *See* Iloprost
6-keto-Prostaglandin $F_{1\alpha}$, 434–435
Prostaglandins, 212, 431
  late responses and, 262
  PLA_2 release and, 33
  pulmonary vascular effects of, 142, 149, 150
  SRS-A and, 307
  See also PGE and PGE_2; PGI_2
Prostacyclin synthetase, 243
Protein kinase C (PKC), 153, 154, 209–210, 212, 242, 243, 252, 254–256, 258, 379–381
  as regulator of PMNL, 187, 190–193
Psoriasis, 309
Psoriatic scale, 252
Psoriatic skin lesions, 218, 252
Pulmonary arteries, vasomotor effects of LTC_4 and LTD_4 on, 91–102
Pulmonary edema, high-altitude, 340
Pulmonary hypertension of the newborn, persistent, 340
Pulmonary vascular bed, 142–152

Radical leakage during LO catalysis, 385–387
Radioprotection, LTC_4 and, 431–433
Ragweed-sensitized dogs, 402–404
Receptors, 374–376
  antagonists to, 356–368
    endotoxemia and, 423–425
    on human airways, 181–186
    hydroxyacetophenone moiety, 452–453
    in LTB_4 binding, 196–200
    See also Antagonists, leukotriene; ICI 198,615
  downregulation of, 464
  mechanisms of regulation of, 153–161
  metabolism of, in ileum, 448–451
  regulation of, for LTB_4 on human neutrophils, 187–195
Renal elimination. *See* Urine
Reperfusion injury, neutrophils and, 103–121
REV5901, 374
Rheumatoid arthritis, 309, 353
RU 33730, 231, 233, 235
Ryanodine, 77, 83, 85

S-26431, 398–401
SAR, 460
SC 39070, 357, 359–360
Second messenger signal, 208–217
Shock. *See* Anaphylactic shock; Endotoxemia
Signal transduction process for LTD_4, 153–161
SK&F 102,922, 408–410
SK&F 104,353, 360–361, 408–410, 423–425, 462
SKF-525A, 99
Slow-reacting substance of anaphylaxis (SRS-A), 122, 127, 133, 142, 196, 283, 298, 307–308, 310, 321, 356–357, 362
  antagonists to. *See* Antagonists, leukotriene
  cardiovascular effects of, 321, 322, 324
Smooth muscle cells, eicosanoids and, 411–413
Snake venoms, lipoxin and leukotriene releases by, 27–34
Structure-activity relationships
  of analogues of LTD_4, 438–441
  ICI 198,615 and, 458–461
Structure elucidation of leukotrienes, 35
Structure-function study of acute lung injury, 271–281
Sulfidopeptide leukotrienes. *See* LTC_4; LTD_4; LTE_4
Superoxide anion (O_2^-), 275
Superoxide release, 242
Suppressor cell activation, 220–223

T cells
metabolites of AA and, 201–207
IL-2 regulation of, 237
suppressor
15-LO and, 241, 242
LTB_4 and, 345–347
$T4^+$ and $T8^+$ subsets of, 221–224
Thoracic aorta, vasomotor effects of leukotrienes on, 91, 94–96
Thromboxane, 262, 434–435
Thymocytes, 222, 227–239
Thyrotropin-releasing hormone (TRH), 325
Tissue trauma, 329
Tocopherol, 385–387, 395–397
Trachea, LT antagonists' effect on, 408–410
Tumor necrosis factor (TNF-α), 224

U937 cells, 154–158
Ulcerative colitis, 309
Urine
leukotriene excretion in, 59, 65
LTC_4 metabolites in, 68
LTE_4 in, human urine, 72–74
measurement of cysteinyl leukotrienes in, 70–72

Vascular cells, LO synthesis by, 122–132
Vascular pressure, LTD_4 and, 420–422
Vasoconstriction, 91, 101, 109, 128, 420–422
Vasomotor effects of leukotrienes, 91–102
Vasorelaxation, endothelium-dependent, 91, 93, 100, 101
Vasospasm, LTC_4 and, 122
Vesicular gland, enzyme immunoassay for cyclooxygenase in, 23–24

Zymosan, 252–258, 275, 278, 336, 337

Index of Contributors

Abraham, W. M., 260–270
Abram, T. S., 448–451
Aharony, D., 162–180
Albertine, K. H., 271–281
Alfaro, D., 428–430
Anderson, W., 438–441
Antôniw, J. W., 133–141
Austen, K. F., xi–xxv

Ball, H. A., 68–74
Barnes, N., 369–378
Baud, L., 345–355
Beck, A., 438–441
Becker, A. B., 402–404
Behrens, T., 201–207
Bell, R. L., 398–401
Bernstein, P., 298–306
Bertsch, B. A., 445–447
Bhattacherjee, P., 307–320
Björnsson, Ó. G., 75–90
Blumberg, J. B., 395–397
Bockman, R., 428–430
Bonne, C., 414–417
Bonvini, E., 379–381
Boughton-Smith, N. K., 307–320
Braquet, P., 454–455
Brash, A. R., 12–26
Bray, M. A., 438–441
Brown, F. J., 458–461
Buckner, C. K., 181–186
Buehn, M. J., 420–422
Bull, H. G., 1–11

Castleman, W. L., 181–186
Chang, J., 442–444
Chang, S., 428–430
Chavaillaz, P-A., 218–226
Cirillo, R., 321–333
Cloud, M. L., 356–368
Cogny Van Weydevelt, F., 227–239
Costello, J., 369–378
Cronk, L. A., 458–461
Crooke, S. T., 153–161, 462–464
Cuthbert, N. J., 448–451

Dabney, J. M., 420–422
Dassoupoulos, T., 434–435
Delebassee, S., 227–239
Dietrich, S., 442–444
Dobbins, D. E., 420–422
Drazen, J. M., 289–297

Eckardt, R. D., 423–425
Ehara, H., 12–26
Eriksson, E., 345–355
Etienne, A., 454–455
Evans, J., 369–378

Falcone, R. C., 162–180
Feinmark, S. J., 122–132
Feuerstein, G., 417–419
Fitzsimmons, B. J., 12–26
Fleisch, J. H., 356–368, 452–453
Fleisher, L. N., 426–427
Follenfant, R. L., 307–320

Gagnon, L., 218–226
Gapinski, D. M., 452–453
Gardiner, P. J., 448–451
Garland, L. G., 307–320
Gee, M. H., 271–281
Giles, R. E., 162–180
Giordano, A., 321–333
Gleason, J. G., 408–410
Goetzl, E. J., 345–355
Goldman, D. W., 187–195
Goodwin, J. S., 201–207
Gorman, R. R., 196–200
Gottlieb, J. E., 271–281
Gualde, N., 227–239
Guhlmann, A., 68–74

Hagmann, W., 68–74
Hajjar, D. P., 411–413
Hajjar, K. A., 411–413
Hall, R. F., 408–410
Hammarström, S., 43–67
Hammerbeck, D. M., 398–401
Harvey, J. P., 345–355
Hattori, A., 12–26
Hay, D. W. P., 408–410
Hebbel, K. C., 458–461
Heghinian, K., 398–401
Heinemann, M. H., 428–430
Her, E., 456–457
Hesp, B., 162–180
Higgs, G. A., 307–320
Ho, P. P. K., 445–447
Hodson, H. F., 307–320
Hoffman, T., 379–381
Huber, M., 68–74
Humes, J. L., 252–259
Hupperts, A. M., 398–401
Hyman, A. L., 142–153

Islip, P. J., 307–320

Jackson, W. P., 307–320
Johnson, H. M., 208–217
Jugus, M., 423–425

Kadowitz, P. J., 142–152
Kaneko, S., 12–26
Kästner, S., 68–74
Kemal, C., 382–384, 385–387, 388–390
Keppler, A., 43–67
Keppler, D., 68–74
Kern, R., 298–306
Kinter, L. B., 423–425
Komatsu, N., 12–26
Koo, C. H., 345–355
Kraemer, R., 103–121
Krell, R. D., 162–180, 298–306, 458–461
Krupinski-Olsen, R., 382–384, 385–387

Lam, B. K., 27–34
Lang, R. W., 438–441
Latanza, L., 428–430
Lavaud, P., 454–455
Lee, C-Y., 27–34
Lefort, J., 405–407
Letts, G., 417–419
Levi, R., 91–102
Lichtenstein, L. M., 334–344
Lin, A. H., 196–200
Lizzio, E. F., 379–381
Louis-Flamberg, P., 382–384, 388–390

Marcus, A. J., 411–413
Märki, F., 438–441
Marone, G., 321–333
Marshall, L., 442–444
Marshall, W. S., 356–368
Maruyama, T., 12–26
Mary, A., 414–416
McNamara, D. B., 142–153
Mencia-Huerta, J-M., 454–455
Meydani, M., 395–397
Meydani, S. N., 395–397
Mihelich, E. D., 445–447
Modat, G., 414–416
Moncada, S., 307–321
Mong, S., 153–161, 462–464
Montcalm, E., 436–438
Morgan, B. P., 445–447
Morris, J., 196–200
Moshonov, S., 456–457
Muccitelli, R. M., 408–410
Mullane, K. M., 103–121
Muller, A., 414–416
Murphy, R. C., 35–42

Newton, J. F., 423–425

O'Byrne, P. M., 282–288
Ogburn, P. L., Jr., 434–435
Olson, N. C., 426–428
Örning, L., 43–67

Patterson, R., 298–306
Payne, A. N., 307–320
Peters, S. P., 271–281
Piper, P. J., 133–141, 369–378
Prasad, G., 393–394
Pretolani, M., 405–407

Raible, D. G., 334–344
Randall, R. W., 307–320
Rao, M. K., 393–394
Ratnoff, W. D., 345–355
Reddanna, P., 391–392, 393–394
Reddy, C. C., 391–392, 393–394
Reiter, M. J., 398–401
Reynolds, C. H., 307–320
Rinkema, L. E., 452–453
Roberts, J. D., Jr., 434–435
Rokach, J., 12–26
Rola-Pleszczynski, M., 218–226
Roman, C. R., 452–453
Rouzer, C. A., 1–11
Russell, J. K., 208–217
Rustad, M. A., 398–401

Saban, R., 181–186
Sakuma, I., 91–102
Salmon, J. A., 307–320
Sarau, H. M., 153–161
Scherrer, R. A., 398–401
Seaman, W. E., 345–355
Shapiro, A. C., 395–397
Shea-Donohue, T., 436–437
Sherman, J. W., 345–355
Shorter, A. L., 382–384, 388–390
Simons, K. J., 402–404
Siren, A-L., 417–419
Smith, E. F., III, 423–425
Smith, L. J., 298–306
Snyder, D. W., 458–461
Soberman, R. J., xi–xxv
Stanton, A. W. B., 133–141
Stelzer, V. L., 398–401
Stene, D. O., 35–42
Stocking, L. M., 395–397
Suissa, J., 379–381
Swingle, K. F., 398–401

Talmon, J., 456–457
Tateson, J. E., 307–320

Thornberry, N. A., 1–11
Torphy, T. J., 408–410
Torres, B. A., 208–217
Touvay, C., 454–455
Triggiani, M., 321–333
Tucker, S. S., 408–410

Ueda, N., 12–26

Vanderhoek, J. Y., 240–251
Vargaftig, B. B., 405–407
Vegesna, V. K., 153–161
Vigorito, C., 321–333
von Sprecher, A., 438–441

Walden, T. L., Jr., 431–433
Walker, J. L., 434–435
Walters, C. P., 445–447
Wasserman, M. A., 408–410
Watanabe, K., 12–26
Westlin, W., 103–121
Whelan, J., 391–392, 393–394
Whittle, B. J. R., 307–320
Will, J. A., 181–187
Williamson, J. R., 75–90
Winkler, J. D., 153–161, 462–464
Wishka, D. G., 196–200
Wong, P. Y-K, 27–34

Yamamoto, S., 12–26
Yee, Y. K., 162–180, 458–461
Yokoyama, C., 12–26
Yoshimoto, T., 12–26
Yuan, L-C., 385–387

Zakrzewski, J., 369–378
Zor, U., 456–457